Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8952W HIGH $2.66
Volume
1.22 M
Value Traded
3.22 M
Short % Float
1.61%
Days to Cover
1.0
+3.52%Week
+2.32%1 Month
+50.57%3 Month
+76.67%6 Month
-92.4%5 Year
-91.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
114.24 M
EPS (TTM)
-1.69
P/E Ratio
-
Ent. Value
1.98 M
Total Shares
42.94 M
Float Shares
27.14 M
Insiders
19.60%
Institutions
37.23%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
RPTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Repare Therapeutics Inc.
Past FDA Catalysts and PDUFA Decisions
How RPTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | RP-1664 (PLK4 inhibitor) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RP-3500 Small moleculeCompletedNCT04497116 | Advanced Solid Tumor | Phase 1/2 | COMPLETED | 276 | Jun 13, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every RPTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| lunresertib and camonsertib | endometrial cancer and platinum-resistant ovarian cancer | Phase 1 | 2024-12-12 | overall response rate endometrial cancer: 25.9%; overall response rate ovarian cancer: 37.5%; progression free survival 24 weeks: nearly half of patientsRead More | Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial Heavily-pretreated patients on lunresertib and camonsertib combinRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Koehler MariaOfficer (EVP, CHIEF MEDICAL OFFICER) | Sell | -3,596 227,813 held | $1.14 | 03/12/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in RPTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 0.9 % (28.6 %) | 26.87 M | 10.33 M |
Ownership Trends
RPTX Short Interest
Shares sold short, counted twice a month.
1.61%
Short % of Float
of tradable shares sold short
437.9K
Shares Sold Short
+125.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
984.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RPTX ranks across every disease it competes in
Competitive Position is a premium feature
See how RPTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRPTX News
About Repare Therapeutics Inc.
Founded19-06-2020
BIOPHARMAWATCH ELITE PLUS
Trade the next RPTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime